A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z   A-M   N-Z   1  2  3  4  5  6  7  8  9 


#11412: Acetylcholine Receptor Blocking Autoantibodies
(AChR)

COMPONENTS
Name Method Reference Range Units
AChR Blocking Autoantibodies RIA < 15 % 

SPECIMEN REQUIREMENTS
No Type Volume Temperature Container Type Instructions
1 Serum 1 (0.2) mL Ambient - 7 Day(s)/Refrigerated - 14 Day(s)/Frozen - 2 Month(s) Aliquot  

GENERAL INFORMATION
Setup Schedule Wednesday
Reported 2 days
CPT Code 83519
Notes Prices might not include a handling fee.
Clinical Utilities Myasthenia gravis (MG), the most common neuromuscular transmission disorder, is an antibody-mediated autoimmune disease that stems from a loss of acetylcholine receptors (AChR) at neuromuscular junctions. AChR autoantibodies are diagnostic of MG, and are found in 85-90% of MG patients. AChR binding autoantibodies are present most frequently in MG and provide the most reliable information for diagnostic screening. A small portion of patients with early onset or ocular restricted MG may only have AChR modulating autoantibodies, thus if AChR binding autoantibodies are absent in a patient with weakness or ocular symptoms consistent with MG, AChR modulating autoantibodies should be ordered. AChR blocking autoantibodies are directed against the neurotransmitter-binding site and may be the only AChR autoantibody in about 1% of MG patients.